drugset / Trial / NCT03197766

A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

NCT03197766

Phase 3 Completed 121 enrolled BioMarin Pharmaceutical
RandomizedParallel-groupTriple-blindTreatment

Summary

The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia.

Timeline

Start
2016-12-12
Primary completion
2019-10-30
Completion
2019-10-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Vosoritide Peptide 15 ug/kg Subcutaneous

Indications